Drug Profile
Recombinant human thrombopoietin - Sansheng Pharmaceutical
Alternative Names: rhTPO -Sansheng PharmaceuticalLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Sansheng Pharmaceutical
- Class Recombinant proteins
- Mechanism of Action Thrombopoietin receptor agonists; Thrombopoietin stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophagocytic lymphohistiocytosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Haemophagocytic lymphohistiocytosis in China (SC, Injection)